Clinical Trials Logo

Filter by:
NCT ID: NCT02460458 Active, not recruiting - Clinical trials for Type 3 Von Willebrand's Disease

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

3WINTERSIPSEXT
Start date: November 5, 2012
Phase:
Study type: Observational

International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.

NCT ID: NCT02453984 Active, not recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

MPDL3280A-imaging-IST-UMCG

Start date: February 24, 2016
Phase: N/A
Study type: Interventional

By performing a 89Zr-MPDL3280A-PET scan prior or during treatment with MPDL3280A, the uptake of the tracer in the primary and metastatic tumor lesions and normal organ distribution can be evaluated, as well as the use of a 89Zr-MPDL3280A-PET as a complementary tool for patient selection and MPDL3280A- target saturation during treatment.

NCT ID: NCT02453282 Active, not recruiting - Clinical trials for Non-Small-Cell Lung Carcinoma NSCLC

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

MYSTIC
Start date: July 21, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

NCT ID: NCT02451943 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

ANNOUNCE
Start date: September 14, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.

NCT ID: NCT02437279 Active, not recruiting - Clinical trials for Stage III Skin Melanoma

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

OpACIN
Start date: November 24, 2016
Phase: Phase 1
Study type: Interventional

This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.

NCT ID: NCT02436733 Active, not recruiting - Clinical trials for Malignant Pleural Mesothelioma

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Start date: September 20, 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between Arm A: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75 mg/m2, both drugs given on day 1, every three weeks) Arm B: three cycles of chemotherapy (same regimen) followed by P/D, for non-progressing patients

NCT ID: NCT02428582 Active, not recruiting - Arteriosclerosis Clinical Trials

Covered Stents Versus Bare-Metal Stents

Start date: May 2016
Phase: N/A
Study type: Interventional

To compare the outcome of revascularisation the gastrointestinal arteries using covered stents compared to bare-metal stents in patients with CGI.

NCT ID: NCT02422888 Active, not recruiting - Clinical trials for Myocardial Infarction

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

REDUCE-MVI
Start date: May 2015
Phase: Phase 4
Study type: Interventional

The current trial will compare the protective effect of ticagrelor and prasugrel on microvascular dysfunction in patients with revascularized ST elevation myocardial infarction.

NCT ID: NCT02396459 Active, not recruiting - Clinical trials for Allan-Herndon-Dudley Syndrome

Triac Trial II in MCT8 Deficiency Patients

Start date: December 7, 2020
Phase: Phase 2
Study type: Interventional

This study will investigate the effect of treatment with tiratricol (also called Triac) in young boys (≤30 months) with MCT8 deficiency (also called the Allan-Herndon-Dudley syndrome (AHDS)). The hypothesis tested is that treatment with tiratricol will have a beneficial effect on the hypothyroid state in the brain as well as the hyperthyroid state in peripheral organs and tissues in these patients. Patients will initially be treated for 96 weeks with tiratricol, treatment effect on neurodevelopment impairment caused by hypothyroidism and peripheral thyrotoxicosis will be evaluated after 96 weeks treatment. Patients will be offered to continue on treatment for an additional 2 years.

NCT ID: NCT02394080 Active, not recruiting - Clinical trials for Acute Humerus Fractures

Safety and Efficacy Study of the Treatment of Humerus Fractures

Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to collect safety and performance data on the use of the Photodynamic Bone Stabilization System (PBSS) when used to provide stabilization and alignment for the treatment of acute humerus fractures.